AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
“Execution, execution, execution”: Intel CEO vows to rebuild through results
2
Cyber startup Cyera raising hundreds of millions at over $6 billion valuation
3
Intel considering selling off networking business in strategic overhaul
4
Wiz 2.0? Cyera’s meteoric $6B valuation is turning heads across the cyber world
5
“House of cards is beginning to crumble”: Deel targets Rippling over alleged witness payments
More news

Cancer

20 stories about Cancer
STS product TechnoPulm

TechnoPulm raises $2 million to develop a handheld device capable of performing full lung function tests

10.10.24|James Spiro
The company took part in CTech’s Startup Boarding Pass series to share how its technology will change lung function testing for millions of Americans. 
Miri Debbie Sheba

The end of missed diagnoses? How AI is detecting breast cancer cases that physicians overlook

09.10.24|Dr. Debbie Anaby, Prof. Miri Sklair-Levy
"The future of AI in medicine is only at its beginning. The digital revolution is no longer a futuristic dream—it is happening now," write Professor Miri Sklair-Levy and Dr. Debbie Anaby.
מייסד אורקל לארי אליסון

Larry Ellison-backed Israeli startup Imagene and Oracle unveil AI model for cancer detection

10.09.24|Sophie Shulman
The startup has launched the CanvOI model, powered by Oracle Cloud, to advance cancer treatment. 
Cyber Edge

Israel's "groundbreaking" cancer treatment and a new $35 million Seed round?

14.06.24|Elihay Vidal
Our AI-generated hosts talk through some of tech's biggest stories this week 
New Phase

Groundbreaking Israeli cancer treatment gets FDA approval for clinical trials in U.S.

09.06.24|Ariela Karmel
New Phase CEO Ofer Shalev spoke to CTech about their technology which turns advanced cancer into a chronic ailment, extending the lifespans and treating symptoms without any of the side effects associated with other existing treatments 
מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
מייסדי אייבקס, מימין: ד"ר חיים לינהרט ויוסי מוסל

Ibex Medical raises $55 million Series C for AI-powered cancer diagnostics

06.09.23|Meir Orbach
The Israeli startup’s platform provides health systems and diagnostic laboratories with an integrated solution for cancer diagnosis and biomarker scoring, capable of detecting more than 100 different cancer and non-cancer pathologies
צוות Nectin Therapeutics

Nectin Therapeutics raises $25 million Series A to treat advanced cancer tumors

30.11.22|Meir Orbach
The Israeli company is aiming to achieve new standards for efficacy and patient response across a number of difficult-to-treat cancers
Itay Barnea BioProtect

Is it time to reconsider PSA tests for Prostate Cancer?

01.09.22|Itay Barnea
“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect
Dr. Ofer Sharon - OncoHost CEO

Collaboration is the key to advancing cancer care

30.08.22|Ofer Sharon
Israel can become a precision oncology powerhouse, but we need to change direction, writes Dr. Ofer Sharon, CEO of OncoHost
Spotitearly team

SpotitEarly raises $6.2 million for early detection of cancers based on olfactory abilities of dogs

23.06.22|CTech
Each type of cancer has a unique odor, and most also have a common denominator. Dogs can detect these odors in a fraction of a second
מייסדי Imagene AI. מימין: יהונתן צלח, דין ביתן, שחר פורת והמדענית הראשית ד"ר נורית פז

Larry Ellison leads $21.5 million Series A in cancer treatment startup Imagene AI

02.05.22|Meir Orbach
Using only a digitized biopsy image, the Israeli startup’s diagnostic technology delivers real-time molecular analysis, increasing the level of accuracy and reducing the time required for results, from several weeks to just two minutes
מוסף שבועי 9.12.21 ד"ר ארנה ברי

“I still feel like Cinderella and that I’m here by mistake”

16.04.22|Diana Bahur-Nir
After beating multiple cancers, former Chief Scientist Orna Berry turned being a cancer survivor into a hobby
מעבדה רפואה 1 זירת הבריאות

Nucleix announces $22 million in funding, advancements in lung cancer detection program

05.01.22|Meir Orbach
The Israeli company develops non-invasive, DNA methylation-based cancer screening tests for early-stage and recurring cancer detection
יחזקאל ברנהולץ Ayana Pharma

Israeli companies send nanotechnology cancer treatment experiment to space aboard SpaceX

26.12.21|CTech
The drug, developed in Israel by Ayana Pharma, will be tested under zero-gravity conditions after being launched last week in a smart laboratory belonging to Israeli company SpacePharma aboard Elon Musk's Falcon 9 launcher
ירון פרג מנכל כאהר מדיקל

KAHR announced $46.5 million funding round to advance its immunotherapeutic pipeline

16.06.21|James Spiro
The round will be used to advance the clinical development of KAHR’s lead product candidate, DSP107
Joseph Mossel

Ibex Medical Analytics granted ‘Breakthrough Device Designation’ by the FDA, fast-tracking its approval

09.06.21|James Spiro
The U.S Food and Drug Administration formally acknowledged its Galen platform and the potential benefit it has on American patients
IBEX CE approved

Ibex obtains CE Mark for AI-powered breast cancer detection

26.05.21|James Spiro
The Ibex Galen Breast solution can detect multiple types of breast cancer and provide accurate diagnoses
אייסקיור הליך הקפאת גידול בשד

Israel’s IceCure granted FDA Breakthrough Medical Device designation

04.04.21|Hezi Sternlicht
The decision puts the company’s tumor-freezing technology on the fast track for final approval
Joseph Mossel

Ibex Medical Analytics raises $38 million for AI-powered cancer diagnostics solutions

09.03.21|Meir Orbach
Ibex’s solutions detect cancer in real-time, enabling 100% quality control, while also reducing turnaround times
More Articles